Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2024 Q2 | Aug 6, 2024 | Long Cast Advisers | 6.0% | 16.0% | MTRX, RSSS | - | View | ||
| 2025 Q3 | Nov 24, 2025 | Long Cast Advisers | 4.0% | -1.0% | MTRX, PDEX, PESI, QRHC, RSSS | Compounding, industrials, Inefficiency, SmallCaps, valuation | The manager reiterates that small-cap inefficienciesparticularly in niche industrials and underfollowed service companiescreate persistent mispricings. The letter shows several examples where revenue durability and strong balance sheets remain underappreciated by the market despite cyclical noise. Small caps remain attractive for patient investors seeking idiosyncratic compounders with valuation dislocations. | QRHC PESI RSSS MTRX PDEX |
View |
| 2025 Q4 | Jan 24, 2026 | Long Cast Advisers | 1.0% | 0.0% | CCRD, CCRN, EEFT, LSYN, MAMA, MTRX, NRC, PDEX, PESI, QRHC, RELL, RSSS | healthcare, Owner-Operator, small caps, Staffing, value | Significant focus on healthcare staffing through CCRN investment, with nurse staffing industry facing competitive pressures but potential for margin improvement. Also invested in NRC, a healthcare consulting and patient survey company with strong margins despite industry headwinds. Portfolio concentrated in small and micro-cap companies with intent to own for multiple years. Manager emphasizes patient capital approach targeting 15% annualized returns through well-researched small company investments. Focus on companies trading at attractive valuations with strong balance sheets and cash positions. CCRN example shows investment in company with 40% of market cap in cash and low enterprise value multiples. | RSSS MTRX NRC CCRN |
View |
| 2023 Q4 | Feb 29, 2024 | Artko Capital | 6.9% | 1.6% | ACFN, CURN, HQI, MLP, NTIC, PBPB, POL, RSSS, SHYF | - | View | ||
| 2022 Q4 | Feb 16, 2023 | Artko Capital | 6.9% | 1.6% | ACFN, CURN, GAIA, HQI, NTIC, PBPB, POL, RSSS, SHYF | - | View | ||
| 2023 Q4 | Feb 13, 2024 | Long Cast Advisers | 6.0% | 16.0% | CCRD, MAMA, MTRX, PESI, QRHC, RSSS | - | View | ||
| 2022 Q4 | Jan 31, 2023 | Long Cast Advisers | 6.0% | 16.0% | AMPX, CCRN, ENVX, RSSS | - | View | ||
| 2024 Q4 | Jan 24, 2025 | Long Cast Advisers | 20.0% | 39.0% | CCRD, MTRX, PDEX, PESI, QRHC, RSSS | - | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Jan 27, 2026 | Fund Letters | Avram Fisher | Research Solutions, Inc. | Information Technology | Software | Bull | NASDAQ | contrarian, marketshare, research, Software, Subscriptions | View Pitch |
| Nov 28, 2025 | Fund Letters | Avram Fisher | Research Solutions, Inc. | Information Technology | Application Software | Bull | NASDAQ | AI, Curation, Data, research, SaaS, Smallcap, Subscriptions | View Pitch |
| Sep 21, 2025 | Substack | Jam Invest | Research Solutions, Inc. | Technology | Software - Application | Neutral | AI, cash position, compliance management, information services, M&A, recurring revenue, research platform, Research Solutions, SaaS | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||